Zobrazeno 1 - 10
of 27
pro vyhledávání: '"David L Kok"'
Autor:
Julia Lai-Kwon, Robyn Woodward-Kron, David Seignior, Louise Allen, Grant McArthur, Michelle Barrett, David L Kok
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Evaluations of continuing professional development programs typically focus on short-term knowledge and skill acquisition. There is a need for more comprehensive program evaluation methods that assess a broader range of impacts an
Externí odkaz:
https://doaj.org/article/636f98636fc244b8a6bf8fcdd16bc4ba
Autor:
Julia Lai-Kwon, Sathana Dushyanthen, David Seignior, Michelle Barrett, Femke Buisman-Pijlman, Andrew Buntine, Robyn Woodward-Kron, Grant McArthur, David L Kok
Publikováno v:
BMC Medical Education, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Improving oncology-specific knowledge and skills of healthcare professionals is critical for improving the outcomes of people with cancer. Many current postgraduate education offerings may be inaccessible to busy professionals, co
Externí odkaz:
https://doaj.org/article/17ce1a7e9b074a8881a7d8efc158750f
Autor:
David L. Kok, Sathana Dushyanthen, Gabrielle Peters, Daniel Sapkaroski, Michelle Barrett, Jenny Sim, Jesper Grau Eriksen
Publikováno v:
Technical Innovations & Patient Support in Radiation Oncology, Vol 24, Iss , Pp 86-93 (2022)
The field of radiation oncology is rapidly advancing through technological and biomedical innovation backed by robust research evidence. In addition, cancer professionals are notoriously time-poor, meaning there is a need for high quality, accessible
Externí odkaz:
https://doaj.org/article/3f0d03542a5b4152b5fb46dadc3b392d
Publikováno v:
Clinical Colorectal Cancer. 21:e179-e186
Autor:
Annie J. Wang, Brendan McCann, William C. L. Soon, Paolo B. De Ieso, Mathias Bressel, Andrew Hui, Margaret Chua, David L. Kok
Publikováno v:
BMC Cancer. 23
Background Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin malignancy, with Australia having the highest reported incidence in the world. There is currently a lack of consensus regarding optimal management of this dise
Autor:
Annie J, Wang, Brendan, McCann, William C L, Soon, Paolo B, De Ieso, Mathias, Bressel, Andrew, Hui, Margaret, Chua, David L, Kok
Publikováno v:
BMC cancer. 23(1)
Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin malignancy, with Australia having the highest reported incidence in the world. There is currently a lack of consensus regarding optimal management of this disease.This wa
Publikováno v:
Melanoma research. 32(3)
Melanoma remains a large global burden with a significant proportion of patients succumbing to metastatic disease. The adrenal gland is a common area for metastasis with surgical treatment as the main modality. Radiotherapy is less utilised in this s
Autor:
Richard W. Tothill, Ganessan Kichendasse, Julie Howle, David L Kok, Michael J. Veness, Annie Wang, Margaret Chua, Shahneen Sandhu, Gerald B Fogarty, Michael Poulsen, Wen Xu, Alexander Guminski
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine tumor of the skin with an estimated disease‐associated mortality of 15–33%. Australia has a higher incidence of MCC compared to the rest of the world, thought to be due to a higher
Publikováno v:
Radiotherapy and Oncology. 142:27-35
Background: Following the resection of brain metastases, Stereotactic Radiosurgery (SRS) to the post-operative surgical cavity has increasingly replaced Whole Brain Radiotherapy (WBRT) as the standard of practice. There is however tremendous variatio
Autor:
David L Kok, Belinda Lee, Ramyar Molania, Alison Weppler, Shahneen Sandhu, Grant A. McArthur, Benjamin Solomon, Kortnye Smith, Han Xian Aw Yeang, Tony Papenfuss, Ismael A. Vergara, Peter Lau, Paul J Neeson, Amir Iravani, Karen E. Sheppard, Christopher Angel, Breon Feran, Arian Lasocki, Kate Drummond, Damien Kee, Richard J. Young, Prachi Bhave, Lorey K. Smith
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundMelanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab–nivolumab have similar intracranial response rates (50%–55%), central nerv